Roche Aims to Cut Costs and Raise Productivity - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Roche Aims to Cut Costs and Raise Productivity

ePT--the Electronic Newsletter of Pharmaceutical Technology

On Sept. 3, 2010, Roche (Basel) launched a groupwide operational-excellence initiative intended to modify the company’s cost structures and accelerate its productivity improvements. Under the initiative, all parts of the company will analyze their respective structures and processes. By the end of the year, the company will decide what measures it will take and evaluate their potential effects on staffing levels. Roche plans to implement its operational-excellence initiative during 2011 and 2012.
In a press statement, Roche cited mounting pressures to curb healthcare costs in the United States and Europe as one reason for the initiative. Recent disappointments in Roche’s late-stage pipeline, including the discontinuation of the clinical-development program for the rheumatoid-arthritis drug ocrelizumab, also prompted the initiative, according to the statement. The company expects healthcare payers to respond to tight budgets by selecting the treatments and diagnostic tools that offer the highest medical value for patients. Thus, an additional goal of the operational-excellence initiative will be “setting the right priorities to ensure a successful future,” according to the statement.
“We have launched this initiative from a position of strength,” said Severin Schwan, Roche’s CEO, in the press statement. “By contrast with many of our competitors, we are only marginally affected by patent expiries. Furthermore, despite the recent setbacks, we have one of the strongest research-and-development product pipelines in the industry. We will focus our resources toward investments that will drive innovation and ensure the company’s long-term success, while at the same time protecting our profitability so as to safeguard our financial flexibility.” In the statement, Schwan confirmed Roche’s full-year outlook for 2010.
See related PharmTech articles:
An Ounce of Prevention (PharmTech)

Big Pharma's Manufacturing Strategy: What is the Next Move? (PharmTech)


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here